semaglutide and epilepsy Semaglutide-induced status epilepticus | Clinical Epileptology Does Wegovy Cause Seizures? UK

The Clinical Data: Everything Published So Far Phase 1 First-in-Human (Oral Formulation) Published: The Lancet, June 2025 Participants: 144 adults with overweight or obesity (BMI 25.039.9), no diabetes Duration: Up to 12 weeks Dosing: Once-daily oral amycretin, up to 2 50 mg Results: - 50 mg dose: 10.4% mean body weight change - 2 50 mg dose: 13.1% mean body weight change - Placebo: 1.2% 13% weight loss in 12 weeks

So the traditional definition really wants to shape everyone by looking at this idea of body mass index

Each starts at a low dose that can be increased every four weeks as tolerated and needed

These symptoms may indicate complications such as faecal impaction, bowel obstruction, or other serious gastrointestinal conditions requiring investigation

doi:10.2165/00023210-200519030-00003